Safety and Efficacy of EDP1815 in the Treatment of Patients Hospitalized With COVID-19 Infection

Recruiting in Palo Alto (17 mi)

+3 other locations

Overseen by Reynold Panettieri, MD

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 2

Waitlist Available

Sponsor: Evelo Biosciences, Inc.

Prior Safety Data

Trial Summary

What is the purpose of this trial?

Evelo will investigate the safety and efficacy of EDP1815 in the treatment of patients hospitalized with SARS-CoV-2 Infection

Eligibility Criteria

Inclusion Criteria

18-65 years old, OR >65 year-olds can be included after Data Monitoring Committee (DMC) approval

Hospitalized within the last 36 hours.

Receiving any form of supplementary oxygen therapy at baseline.

Participant Groups

Group I: EDP1815 Experimental Treatment 1 Intervention

Patients will receive EDP1815 in addition to standard of care

Group II: Placebo Placebo Group 1 Intervention

Patients will receive placebo in addition to standard of care

Find a Clinic Near You

Research Locations Nearby Select from list below to view details:

Robert Wood Johnson University Hospital New Brunswick, NJ

DHR Health Institute Edinburg, TX

The University Hospital Newark, NJ

Who Is Running the Clinical Trial?

Evelo Biosciences, Inc. Lead Sponsor

References